<p>Artisan Partners Limited Partnership 在最近向美國證券交易委員會（SEC）提交的文件中表示，在第二季度減少了對 Replimune Group, Inc.（NASDAQ:REPL - 免費報告）股份的持有，降幅為 9.5%。該機構投資者在季度內出售了 53,704 股後，持有該公司 511,371 股股票。Artisan Partners Limited Partnership 在最近一個季度末持有的 Replimune Group 的股份約佔 0.66%，價值 4,751,000 美元。</p>
<p>獲取 <strong>Replimune Group</strong> 警報：</p>
<ul>
<li>按表現排名的最佳股票選擇 AI</li>
</ul>
<p>其他幾家對沖基金最近也買賣了該公司的股票。Letko Brosseau &amp; Associates Inc. 在第二季度購買了價值約 100,000 美元的 Replimune Group 新頭寸。Candriam S.C.A. 在第二季度購買了價值約 1,594,000 美元的 Replimune Group 新股份。Nan Fung Trinity HK Ltd. 在第二季度購買了價值 4,325,000 美元的 Replimune Group 新頭寸。洛杉磯資本管理公司在第二季度購買了價值約 403,000 美元的 Replimune Group 新股份。最後，AlphaQuest LLC 在第二季度將其在 Replimune Group 的持股增加了 99.9%。AlphaQuest LLC 現在擁有 9,857 股該公司的股票，價值 92,000 美元，此前在上個季度又收購了 4,925 股。機構投資者持有該公司 92.53% 的股票。</p>
<h2>Replimune Group 股票上漲 2.1%</h2>
<p>NASDAQ:REPL 週五開盤價為 9.20 美元。該公司的債務與股本比率為 0.26，速動比率為 6.31，流動比率為 6.31。該公司的市值為 7.2165 億美元，市盈率為 -2.66，貝塔值為 0.80。Replimune Group, Inc. 的一年低點為 2.68 美元，一年高點為 17.00 美元。該股票的 50 天簡單移動平均線為 6.75 美元，200 天簡單移動平均線為 7.40 美元。</p>
<p>Replimune Group（NASDAQ:REPL - 獲取免費報告）最近於 11 月 6 日星期四發佈了季度財報。該公司報告的每股收益（EPS）為 -0.90，低於市場共識預期的 -0.87，差距為 -0.03。賣方分析師預測 Replimune Group, Inc. 本財年的每股收益將為 -2.97。</p>
<h2>華爾街分析師觀點</h2>
<p>幾位股票分析師對 REPL 股票發佈了報告。Leerink Partners 將 Replimune Group 的股票評級從 “市場表現” 上調至 “跑贏大盤”，並在 10 月 20 日的研究報告中將其目標價從 3.00 美元提高至 13.00 美元。摩根大通將 Replimune Group 的股票評級從 “減持” 上調至 “中性”，並在 10 月 20 日的研究報告中設定了 11.00 美元的目標價。Wedbush 將 Replimune Group 的股票評級從 “中性” 上調至 “跑贏大盤”，並在 10 月 20 日的報告中將其目標價從 4.00 美元提高至 18.00 美元。Piper Sandler 將 Replimune Group 的評級從 “中性” 上調至 “增持”，並在 10 月 20 日的報告中設定了 13.00 美元的目標價。最後，HC Wainwright 將 Replimune Group 的評級從 “中性” 上調至 “買入”，並在 10 月 27 日的研究報告中設定了 12.00 美元的目標價。一位研究分析師給予該股票 “強烈買入” 評級，六位給予 “買入” 評級，兩位給予 “持有” 評級，兩位給予 “賣出” 評級。根據 MarketBeat 的數據，Replimune Group 目前的共識評級為 “適度買入”，平均目標價為 9.75 美元。</p>
<p><strong>查看我們最新的 Replimune Group 股票分析</strong></p>
<h2>Replimune Group 的內部買賣</h2>
<p>在相關消息中，內部人士 Konstantinos Xynos 於 11 月 17 日星期一出售了 7,248 股該公司的股票。股票以平均價格 9.10 美元出售，總價值為 65,956.80 美元。交易後，該內部人士直接持有該公司 139,685 股股票，價值約 1,271,133.50 美元。此交易代表其持股減少了 4.93%。該交易已在 SEC 的文件中披露，相關信息可通過此鏈接獲取。此外，內部人士 Christopher Sarchi 於 11 月 17 日星期一出售了 5,208 股 Replimune Group 股票。該股票以平均價格 9.10 美元出售，總交易額為 47,392.80 美元。出售後，該內部人士持有該公司 123,088 股股票，價值 1,120,100.80 美元。這代表其持股減少了 4.06%。有關此交易的更多細節可在官方 SEC 披露中找到。公司內部人士持有該公司 5.20% 的股票。</p>
<h2>Replimune Group 公司簡介</h2>
<p>（免費報告）</p>
<p>Replimune Group, Inc. 是一家臨牀階段的生物技術公司，專注於開發腫瘤溶解免疫療法以治療癌症。該公司的專有腫瘤定向溶解免疫療法產品候選旨在激活免疫系統對抗癌症。其主要產品候選是 RP1，一種選擇性複製的 HSV-1 版本，表達 GALV-GP R(-) 和人類 GM-CSF，目前正在進行針對多種實體瘤的 I/II 期臨牀試驗；並已完成針對皮膚鱗狀細胞癌的 II 期臨牀試驗。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更喜歡的五隻股票比 Replimune Group 更好</li>
<li>投資於建築股票</li>
<li>一項宏偉的 AI 投資？斯坦利·德魯肯米勒的最新科技動態</li>
<li>投資者如何找到最佳的便宜股息股票</li>
<li>12 位分析師剛剛提高了 CrowdStrike 的目標——他們預見了什麼</li>
<li>股票分析師評級和加拿大分析師評級</li>
<li>Palo Alto Networks 股票剛剛回調——這是一個理想的買入區嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVQTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVQTA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Replimune Group 嗎？</h2>
<p>在考慮 Replimune Group 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 Replimune Group 並不在名單上。</p>
<p>雖然 Replimune Group 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

REPL

Artisan合夥資產管理

<p>Artisan Partners Limited Partnership 在第二季度減少了對 Replimune Group, Inc. 的持股比例，下降了 9.5%，目前持有 511,371 股，價值 475 萬美元。Replimune 的股票開盤價為 9.20 美元，市值為 7.2165 億美元。分析師的評級意見不一，普遍共識為 “適度買入”，目標價格為 9.75 美元。同時也有內部人士出售股票的報告</p>

<p>Artisan Partners Limited Partnership decreased its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 9.5% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 511,371 shares of the company's stock after selling 53,704 shares during the quarter. Artisan Partners Limited Partnership owned approximately 0.66% of Replimune Group worth $4,751,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Artisan Partners Limited Partnership 在最近向美國證券交易委員會（SEC）提交的文件中表示，在第二季度減少了對 Replimune Group, Inc.（NASDAQ:REPL - 免費報告）股份的持有，降幅為 9.5%。該機構投資者在季度內出售了 53,704 股後，持有該公司 511,371 股股票。Artisan Partners Limited Partnership 在最近一個季度末持有的 Replimune Group 的股份約佔 0.66%，價值 4,751,000 美元。</p>
</div><p>Get <strong>Replimune Group</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Replimune Group</strong> 警報：</p>
</div><ul>
<li>The Best AI for Picking Stocks, Ranked by Performance</li>
</ul>
<div class="lb-trans"><ul>
<li>按表現排名的最佳股票選擇 AI</li>
</ul>
</div><p>Several other hedge funds also recently bought and sold shares of the company. Letko Brosseau &amp; Associates Inc. purchased a new position in Replimune Group during the 2nd quarter valued at approximately $100,000. Candriam S.C.A. purchased a new stake in shares of Replimune Group during the 2nd quarter valued at approximately $1,594,000. Nan Fung Trinity HK Ltd. purchased a new position in Replimune Group in the second quarter valued at $4,325,000. Los Angeles Capital Management LLC purchased a new stake in Replimune Group during the 2nd quarter worth about $403,000. Finally, AlphaQuest LLC raised its stake in Replimune Group by 99.9% during the 2nd quarter. AlphaQuest LLC now owns 9,857 shares of the company's stock worth $92,000 after acquiring an additional 4,925 shares in the last quarter. Institutional investors own 92.53% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家對沖基金最近也買賣了該公司的股票。Letko Brosseau &amp; Associates Inc. 在第二季度購買了價值約 100,000 美元的 Replimune Group 新頭寸。Candriam S.C.A. 在第二季度購買了價值約 1,594,000 美元的 Replimune Group 新股份。Nan Fung Trinity HK Ltd. 在第二季度購買了價值 4,325,000 美元的 Replimune Group 新頭寸。洛杉磯資本管理公司在第二季度購買了價值約 403,000 美元的 Replimune Group 新股份。最後，AlphaQuest LLC 在第二季度將其在 Replimune Group 的持股增加了 99.9%。AlphaQuest LLC 現在擁有 9,857 股該公司的股票，價值 92,000 美元，此前在上個季度又收購了 4,925 股。機構投資者持有該公司 92.53% 的股票。</p>
</div><h2>Replimune Group Stock Up 2.1%</h2>
<div class="lb-trans"><h2>Replimune Group 股票上漲 2.1%</h2>
</div><p>NASDAQ:REPL opened at $9.20 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 6.31 and a current ratio of 6.31. The company has a market capitalization of $721.65 million, a price-to-earnings ratio of -2.66 and a beta of 0.80. Replimune Group, Inc. has a one year low of $2.68 and a one year high of $17.00. The stock has a 50-day simple moving average of $6.75 and a 200 day simple moving average of $7.40.</p>
<div class="lb-trans"><p>NASDAQ:REPL 週五開盤價為 9.20 美元。該公司的債務與股本比率為 0.26，速動比率為 6.31，流動比率為 6.31。該公司的市值為 7.2165 億美元，市盈率為 -2.66，貝塔值為 0.80。Replimune Group, Inc. 的一年低點為 2.68 美元，一年高點為 17.00 美元。該股票的 50 天簡單移動平均線為 6.75 美元，200 天簡單移動平均線為 7.40 美元。</p>
</div><p>Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.03). Sell-side analysts predict that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Replimune Group（NASDAQ:REPL - 獲取免費報告）最近於 11 月 6 日星期四發佈了季度財報。該公司報告的每股收益（EPS）為 -0.90，低於市場共識預期的 -0.87，差距為 -0.03。賣方分析師預測 Replimune Group, Inc. 本財年的每股收益將為 -2.97。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Several equities analysts have issued reports on REPL shares. Leerink Partners raised shares of Replimune Group from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and boosted their price objective for the company from $3.00 to $13.00 in a research note on Monday, October 20th. JPMorgan Chase &amp; Co. upgraded shares of Replimune Group from an &#34;underweight&#34; rating to a &#34;neutral&#34; rating and set a $11.00 price target on the stock in a research note on Monday, October 20th. Wedbush raised shares of Replimune Group from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and increased their price target for the stock from $4.00 to $18.00 in a report on Monday, October 20th. Piper Sandler raised Replimune Group from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating and set a $13.00 price objective on the stock in a report on Monday, October 20th. Finally, HC Wainwright upgraded Replimune Group from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $12.00 target price on the stock in a research report on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Replimune Group presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $9.75.</p>
<div class="lb-trans"><p>幾位股票分析師對 REPL 股票發佈了報告。Leerink Partners 將 Replimune Group 的股票評級從 “市場表現” 上調至 “跑贏大盤”，並在 10 月 20 日的研究報告中將其目標價從 3.00 美元提高至 13.00 美元。摩根大通將 Replimune Group 的股票評級從 “減持” 上調至 “中性”，並在 10 月 20 日的研究報告中設定了 11.00 美元的目標價。Wedbush 將 Replimune Group 的股票評級從 “中性” 上調至 “跑贏大盤”，並在 10 月 20 日的報告中將其目標價從 4.00 美元提高至 18.00 美元。Piper Sandler 將 Replimune Group 的評級從 “中性” 上調至 “增持”，並在 10 月 20 日的報告中設定了 13.00 美元的目標價。最後，HC Wainwright 將 Replimune Group 的評級從 “中性” 上調至 “買入”，並在 10 月 27 日的研究報告中設定了 12.00 美元的目標價。一位研究分析師給予該股票 “強烈買入” 評級，六位給予 “買入” 評級，兩位給予 “持有” 評級，兩位給予 “賣出” 評級。根據 MarketBeat 的數據，Replimune Group 目前的共識評級為 “適度買入”，平均目標價為 9.75 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Replimune Group</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 Replimune Group 股票分析</strong></p>
</div><h2>Insider Buying and Selling at Replimune Group</h2>
<div class="lb-trans"><h2>Replimune Group 的內部買賣</h2>
</div><p>In related news, insider Konstantinos Xynos sold 7,248 shares of the firm's stock in a transaction on Monday, November 17th. The shares were sold at an average price of $9.10, for a total value of $65,956.80. Following the transaction, the insider directly owned 139,685 shares in the company, valued at approximately $1,271,133.50. This trade represents a 4.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Christopher Sarchi sold 5,208 shares of Replimune Group stock in a transaction on Monday, November 17th. The stock was sold at an average price of $9.10, for a total transaction of $47,392.80. Following the sale, the insider owned 123,088 shares in the company, valued at $1,120,100.80. This represents a 4.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 5.20% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 Konstantinos Xynos 於 11 月 17 日星期一出售了 7,248 股該公司的股票。股票以平均價格 9.10 美元出售，總價值為 65,956.80 美元。交易後，該內部人士直接持有該公司 139,685 股股票，價值約 1,271,133.50 美元。此交易代表其持股減少了 4.93%。該交易已在 SEC 的文件中披露，相關信息可通過此鏈接獲取。此外，內部人士 Christopher Sarchi 於 11 月 17 日星期一出售了 5,208 股 Replimune Group 股票。該股票以平均價格 9.10 美元出售，總交易額為 47,392.80 美元。出售後，該內部人士持有該公司 123,088 股股票，價值 1,120,100.80 美元。這代表其持股減少了 4.06%。有關此交易的更多細節可在官方 SEC 披露中找到。公司內部人士持有該公司 5.20% 的股票。</p>
</div><h2>Replimune Group Company Profile</h2>
<div class="lb-trans"><h2>Replimune Group 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.</p>
<div class="lb-trans"><p>Replimune Group, Inc. 是一家臨牀階段的生物技術公司，專注於開發腫瘤溶解免疫療法以治療癌症。該公司的專有腫瘤定向溶解免疫療法產品候選旨在激活免疫系統對抗癌症。其主要產品候選是 RP1，一種選擇性複製的 HSV-1 版本，表達 GALV-GP R(-) 和人類 GM-CSF，目前正在進行針對多種實體瘤的 I/II 期臨牀試驗；並已完成針對皮膚鱗狀細胞癌的 II 期臨牀試驗。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Replimune Group</li>
<li>Investing in Construction Stocks</li>
<li>A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves</li>
<li>How Investors Can Find the Best Cheap Dividend Stocks</li>
<li>12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming</li>
<li>Stock Analyst Ratings and Canadian Analyst Ratings</li>
<li>Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更喜歡的五隻股票比 Replimune Group 更好</li>
<li>投資於建築股票</li>
<li>一項宏偉的 AI 投資？斯坦利·德魯肯米勒的最新科技動態</li>
<li>投資者如何找到最佳的便宜股息股票</li>
<li>12 位分析師剛剛提高了 CrowdStrike 的目標——他們預見了什麼</li>
<li>股票分析師評級和加拿大分析師評級</li>
<li>Palo Alto Networks 股票剛剛回調——這是一個理想的買入區嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVQTA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=REPL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Replimune Group Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Replimune Group 嗎？</h2>
</div><p>Before you consider Replimune Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Replimune Group 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 Replimune Group 並不在名單上。</p>
</div><p>While Replimune Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Replimune Group 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Artisan 合夥有限合夥公司減少了其在 Replimune Group, Inc. $REPL 的持股量